Many low-income and moderate-income U.S. adults say they would be willing to pay about $18 extra per month for generous coverage for specialty drugs.
A team of researchers backed by Bristol-Myers Squibb Company, New York (NYSE:BMY) — a pharmaceutical company — has presented that finding in a survey report published in the latest issue of Health Affairs, a peer-reviewed academic journal that focuses on health care finance and health care organization.
The team included John Romley, a professor at the University of Southern California (USC); Yuri Sanchez, an economist at Precision Health Economics L.L.C., Los Angeles; Dana Goldman, a professor at USC; and John Penrod, an economist at Bristol-Myers.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Allison Bell
Allison Bell, a senior reporter at ThinkAdvisor and BenefitsPRO, previously was an associate editor at National Underwriter Life & Health. She has a bachelor's degree in economics from Washington University in St. Louis and a master's degree in journalism from the Medill School of Journalism at Northwestern University. She can be reached through X at @Think_Allison.
